On June 17, 2024, Alembic Pharmaceuticals announced that it had received final approval from the US Food & Drug Administration (USFDA) for its Icatibant Injection. This injection, provided in a single-dose prefilled syringe with 30 mg/3 mL concentration (10 mg/mL), is now approved as a generic version of Firazyr Injection by Takeda Pharmaceuticals U.S.A., Inc. …